Idiopathic Pulmonary Fibrosis - Pipeline
Review, H1 2017, provides an overview of the Idiopathic Pulmonary Fibrosis
(Respiratory) pipeline landscape.
Idiopathic pulmonary fibrosis (IPF) is a
progressive and fatal disease characterized by inflammation and scarring of
lung tissue and loss of lung function. Symptoms of IPF include dry cough,
shortness of breath, especially during or after physical activity, lasting
tiredness and weight loss. Risk factors include smoking, environmental
exposure, viral infections, family history and abnormal acid reflux. Treatment
includes antioxidants, biological response modulators, anti-fibrotic agents and
anticoagulants.
Report
Highlights
Publisher's Pharmaceutical and Healthcare
latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2017,
provides comprehensive information on the therapeutics under development for
Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and
latest news and press releases.
The Idiopathic Pulmonary Fibrosis
(Respiratory) pipeline guide also reviews of key players involved in
therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant
and discontinued projects. The guide covers therapeutics under Development by
Companies /Universities /Institutes, the molecules developed by Companies in
Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages
are 1, 17, 13, 1, 56 and 10 respectively. Similarly, the Universities portfolio
in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.
Idiopathic Pulmonary Fibrosis (Respiratory)
pipeline guide helps in identifying and tracking emerging players in the market
and their portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage. The guide is built
using data and information sourced from Publisher’s proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of
the global therapeutic landscape of Idiopathic Pulmonary Fibrosis
(Respiratory).
- The pipeline guide reviews pipeline
therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and
universities/research institutes based on information derived from company and
industry-specific sources.
- The pipeline guide covers pipeline
products based on several stages of development ranging from pre-registration
till discovery and undisclosed stages.
- The pipeline guide features descriptive
drug profiles for the pipeline products which comprise, product description,
descriptive licensing and collaboration details, R&D brief, MoA & other
developmental activities.
- The pipeline guide reviews key companies
involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and
enlists all their major and minor projects.
- The pipeline guide evaluates Idiopathic
Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action
(MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the
dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news
related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)
Reasons
to buy
- Procure strategically important
competitor information, analysis, and insights to formulate effective R&D
strategies.
- Recognize emerging players with
potentially strong product portfolio and create effective counter-strategies to
gain competitive advantage.
- Find and recognize significant and varied
types of therapeutics under development for Idiopathic Pulmonary Fibrosis
(Respiratory).
- Classify potential new clients or
partners in the target demographic.
- Develop tactical initiatives by
understanding the focus areas of leading companies.
- Plan mergers and acquisitions
meritoriously by identifying key players and it’s most promising pipeline
therapeutics.
- Formulate corrective measures for
pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory)
pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and
out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by
recognizing discontinued projects and understand from the know-how what drove
them from pipeline.
Spanning over 254 pages “Idiopathic
Pulmonary Fibrosis - Pipeline Review, H1 2017” report covers Introduction,
Idiopathic Pulmonary Fibrosis - Overview, Idiopathic Pulmonary Fibrosis -
Therapeutics Development, Pipeline Overview, Idiopathic Pulmonary Fibrosis -
Therapeutics Assessment, Appendix. This report covered Companies few are -
AdAlta Ltd, Aeolus Pharmaceuticals Inc, Allinky Biopharma, apceth Biopharma
GmbH, Apellis Pharmaceuticals Inc, Asahi Kasei Pharma Corp, aTyr Pharma Inc,
Biogen Inc, Bioneer Corp, BLR Bio LLC.
Please visit this link for more details: http://mrr.cm/UAJ
Related Reports;
Adrenocortical Carcinoma - Pipeline Review,
H1 2017 - Visit at - http://mrr.cm/UA3
Organophosphate and Carbamate Poisoning -
Pipeline Review, H1 2017 - Visit at - http://mrr.cm/UAU
Find all Pharma
and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare
